Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2024 16:30 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and...
October 30, 2024 17:00 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET

PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial...
October 25, 2024 06:50 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug...
October 24, 2024 06:50 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024

PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will present new pre-clinical data highlighting its...
September 26, 2024 06:50 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug...
September 16, 2024 08:53 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with...
September 16, 2024 06:50 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the...
September 13, 2024 06:50 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution

PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan...
September 11, 2024 06:50 ET | Source: ANI Pharmaceuticals, Inc.; Alimera Sciences, Inc.

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly...
September 10, 2024 14:09 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously...